GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Revenue of GH Research PLC (GHRS)
Revenue in 2023 (TTM): $
According to GH Research PLC's latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of GH Research PLC
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-315,000 | $-41,153,000 | $-35,587,000 | $-35,587,000 |
| 2022 | $ | $-47,000 | $-30,628,000 | $-22,456,000 | $-7,135,000 |
| 2021 | $ | $-19,000 | $-15,081,000 | $-9,202,000 | $-9,211,000 |
| 2020 | $ | $ | $ | $-446,000 | $-446,000 |
| 2019 | $ | $ | $ | $-310,000 | $-310,000 |